This pilot study marks the world’s first clinical evaluation of pure silicon CT detector technology for photon counting CT.
GE believes that the deep silicon photon counting technology will not compromise photon count rate or spectral resolution and will be able to provide outstanding spatial resolution.
Last year, the company acquired Swedish medical equipment manufacturer Prismatic Sensors , which is specialised in developing silicon detectors for photon counting CT.
Using a patented, new method, the company’s deep silicon detector has the ability to absorb very high energy photons to create crisper images when compared to other standard CT scanners.
Photon counting CT is believed to improve traditional CT scan capabilities, including the potential to enhance visualisation of minute details of organ structures and tissue characterisation at a lower radiation dose.
GE Healthcare molecular imaging and computed tomography president and CEO Jean-Luc Procaccini said: “Medical technology providers must develop innovative solutions that make healthcare more human by breaking down barriers so clinicians can work at the top of their game, healthcare systems can operate more efficiently, and patients get the best and most precise care possible.
“While still in development, we believe our photon counting CT with deep silicon detectors has the potential to do just that – providing clinicians and patients with more information sooner to help reduce stress and improve patient outcomes.
“We are confident in the direction we are going with our partners and believe this technology has the potential to be a substantial step forward for CT imaging and patient care.”
Karolinska Institute and MedTechLabs will test and optimise the company’s photon counting CT scanner comprising deep silicon detectors.
In this trial, the organisations will compare participants’ images obtained with the silicon-based system to images acquired using a standard CT scanner.
It will also provide imaging data to optimise image processing.
Later, the research group will conduct studies with large numbers of patients.